key: cord-0717585-q9m6webr
authors: Brzozowski, Kaylen
title: 121. Mucormycosis and COVID-19 in the United States: a Real-World Evidence Analysis of Risk Factors and Survival Among Patients with Mucormycosis, with and without COVID-19 Preceding the Infection
date: 2021-12-04
journal: Open Forum Infect Dis
DOI: 10.1093/ofid/ofab466.121
sha: 39c1acfdd8b338550ad50b5bf5f2849fc0bc243a
doc_id: 717585
cord_uid: q9m6webr

BACKGROUND: Mucormycosis has been associated with COVID-19 infections, notably in India, and known risk factors for mucormycosis such as diabetes mellitus have been studied in this context. This analysis aims to characterize patients in the US with mucormycosis, with and without COVID-19, by risk factor and mortality. METHODS: Data from the TriNetX Research Network representing over 66M de-identified patient-lives in the US was used to examine characteristics and outcomes among mucormycosis patients with and without preceding COVID-19 infection. Patients must have had a mucormycosis diagnosis recorded from 1/1/2020 to 6/8/2020. Patients were then identified as having either a COVID-19 diagnosis or positive SARS-CoV-2 RNA laboratory result (M+COV) or no COVID-19 diagnosis or positive RNA result (MnCOV) any time prior to through one day after the mucormycosis diagnosis. These cohorts were evaluated across characteristics recorded in the EMR within 1 year prior to and including the date of mucormycosis record. Mortality was evaluated with Kaplan-Meier statistics as survival until recorded death on or after mucormycosis diagnosis. RESULTS: Of 302 patients with mucormycosis from 1/1/2020-6/8/2021, 30 patients (10%) had M+COV, and 272 (90%) had MnCOV. Among the M+COV cohort, 22 patients (73%) had mucormycosis recorded within 2 weeks of COVID-19 infection. The M+COV and MnCOV cohorts had majority male sex (60,59%;p=0.93) and a similar prevalence of transplanted organs (40,28%;p=0.16), long-term drug therapy (60,54%;p=0.56), chronic kidney disease (43,31%;p=0.16), and glucocorticoid treatment (67,64%;p=0.76). The M+COV cohort had a greater prevalence of type II diabetes mellitus (67,35%;p< 0.01), acidosis (53,22%;p< 0.01), and posthemorrhagic anemia (43,14%;p< 0.01) than the MnCOV cohort. M+COV patients seem to progress to mortality more quickly than MnCOV patients (p=0.01, see Figure 1). Figure 1. Survival until all-cause mortality after mucormycosis diagnosis, 0-180 days, among patients with (M+COV) and without (MnCOV) COVID-19 preceding the infection. [Image: see text] CONCLUSION: This study found that patients in the US with mucormycosis and current or previous COVID-19 infection have a greater prevalence of underlying conditions, including diabetes, and more rapid progression to mortality than those without COVID-19. The nature of the potential relationship between comorbidities, mucormycosis, and COVID-19 should be explored further. DISCLOSURES: All Authors: No reported disclosures

Background. Mucormycosis has been associated with COVID-19 infections, notably in India, and known risk factors for mucormycosis such as diabetes mellitus have been studied in this context. This analysis aims to characterize patients in the US with mucormycosis, with and without COVID-19, by risk factor and mortality.

Methods. Data from the TriNetX Research Network representing over 66M de-identified patient-lives in the US was used to examine characteristics and outcomes among mucormycosis patients with and without preceding COVID-19 infection. Patients must have had a mucormycosis diagnosis recorded from 1/1/2020 to 6/8/2020. Patients were then identified as having either a COVID-19 diagnosis or positive SARS-CoV-2 RNA laboratory result (M+COV) or no COVID-19 diagnosis or positive RNA result (MnCOV) any time prior to through one day after the mucormycosis diagnosis. These cohorts were evaluated across characteristics recorded in the EMR within 1 year prior to and including the date of mucormycosis record. Mortality was evaluated with Kaplan-Meier statistics as survival until recorded death on or after mucormycosis diagnosis.

Results. Of 302 patients with mucormycosis from 1/1/2020-6/8/2021, 30 patients (10%) had M+COV, and 272 (90%) had MnCOV. Among the M+COV cohort, 22 patients (73%) had mucormycosis recorded within 2 weeks of COVID-19 infection. The M+COV and MnCOV cohorts had majority male sex (60,59%;p=0.93) and a similar prevalence of transplanted organs (40,28%;p=0.16), long-term drug therapy (60,54%;p=0.56), chronic kidney disease (43,31%;p=0.16), and glucocorticoid treatment (67,64%;p=0.76). The M+COV cohort had a greater prevalence of type II diabetes mellitus (67,35%;p< 0.01), acidosis (53,22%;p< 0.01), and posthemorrhagic anemia (43,14%;p< 0.01) than the MnCOV cohort. M+COV patients seem to progress to mortality more quickly than MnCOV patients (p=0.01, see Figure 1 ). Figure 1 . Survival until all-cause mortality after mucormycosis diagnosis, 0-180 days, among patients with (M+COV) and without (MnCOV) COVID-19 preceding the infection.

Conclusion. This study found that patients in the US with mucormycosis and current or previous COVID-19 infection have a greater prevalence of underlying conditions, including diabetes, and more rapid progression to mortality than those without COVID-19. The nature of the potential relationship between comorbidities, mucormycosis, and COVID-19 should be explored further.

Disclosures. Background. Candida species are the most common cause of fungemia and are associated with high mortality. Management concordant with the Infectious Diseases Society of America guidelines and infectious diseases consultation (IDC) have been shown to lower mortality in patients with candidemia. The purpose of this study was to compare in-hospital mortality at a large multi-site healthcare system, including sites providing IDC via telemedicine services, in patients with candidemia with and without IDC.

Methods. This was a retrospective, observational cohort study completed at ten sites of Legacy Atrium Health in Charlotte Metro, NC, USA; at five sites, IDC is performed via telemedicine. Adult hospitalized patients identified with candidemia were enrolled May 2018-June 2019. The primary outcome was in-hospital mortality of IDC and non-IDC patients. Secondary outcomes included obtainment of repeat blood cultures, receipt of antifungal treatment, duration of therapy, removal of central venous lines (CVC) when present, and ophthalmological examination. Fisher's exact, Chi-Square, or two-tailed Student's t-test were used for demographics, primary and secondary outcomes as appropriate.

Results. A total of 126 patients were enrolled: 103 (82%) in the IDC group and 23 (18%) in the non-IDC group (Table 1) . Mortality was significantly lower, and rates of repeat blood culture obtainment and receipt of antifungal treatment were significantly higher in patients with IDC (Table 2) . Other outcomes including duration of therapy, removal of CVC, repeat cultures within 48 hours, and ophthalmological examination were not statistically different between groups.

Conclusion. This study is the first multi-site healthcare system providing telemedicine services to evaluate the impact of IDC on candidemia mortality. Ophthalmological examination rates were low in both groups, highlighting a potential area for improvement. IDC had significantly lower mortality, higher rates of antifungal treatment, and higher rates of repeat blood culture obtainment. IDC should be strongly considered in all patients with candidemia.

Disclosures. All Authors: No reported disclosures

Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)

Prof. 2 ; Philipp Koehler

FRCPath 13 ; Rohit Bazaz, BCh;MB

Brigham and Women's Hospital

Background. Candida species are a major cause of invasive and mucocutaneouls infections. There are limited oral treatment options available for patients with Candida infections who are unresponsive to or who are intolerant of currently available antifungals. Oral ibrexafungerp is an investigational broad-spectrum glucan synthase inhibitor antifungal with activity against Candida and Aspergillus species, including azole-and echinocandin-resistant strains. A Phase 3 open-label, single-arm study of ibrexafungerp (FURI; NCT03059992) is ongoing for the treatment of patients intolerant of or with fungal disease refractory to standard antifungal therapy. We present an analysis of patient outcomes from the FURI study by fungal disease type.